Реноваскулярна хвороба. Сучасний підхід до діагностики та лікування

В.Ю. Кундін, М.В. Сатир, А.В. Хохлов, А.Г. Мазур, І.В. Новерко, М.В. Шиманко

Література 

1. Abela R, Ivanova S, Lidder S. et al. An analysis comparing opensurgical and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc Endovasc Surg. 2009;38(6):666–675.
2. American Society for Testing and Materials (ASTM) International. ASTM F2503-05: Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment. West Conshohocken, Pa: ASTM International; 2005. Available at: http://www.astm.org.
3. Angeretti MG, Lumia D, Canì A. et al. Non-enhanced MR angiography of renal arteries: comparison with contrast-enhanced MR angiography. Acta Radiol. 2013;54 (7):749–756.
4. Balzer KM, Pfeiffer T, Rossbach S. et al. Prospective randomized trial of operative vs interventional treatment for renal artery ostial occlusive disease (RAOOD). J Vasc Surg. 2009;49(3):667–674.
5. Baumgartner I, Lerman LO. Renovascular hypertension: screening and modern management. Eur Heart J. 2011;32(13):1590–1598.
6. Bax L, Woittiez A.J, Kouwenberg H.J. et al. STAR Stent Placement in Patients With Atherosclerotic Renal Artery Stenosis and Impaired Renal Function. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150(12):840–848.
7. Bertino RE, Bluth EI, Frates MC. et al. AIUM practice guideline for the performance of renal artery duplex sonography. J Ultrasound Med. 2009;28(1):120–124.
8. Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol. 2008;180(3):830–835.
9. Bloch M.J, Basile J. The diagnosis and management of renovascular disease: aprimary careperspective. Part I. Making thediagnosis. J Clin Hypertens (Greenwich). 2003;5(3):210–218.
10. Caielli P, Frigo AC, Pengo MF. et al. DRASTIC Dutch Renal Artery Stenosis Intervention Cooperative Study Treatment of atherosclerotic endovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. Nephrol Dial Transplant. 2015;30(4):541–553.
11. Chi YW, White CJ, Thornton S, Milani RV. Ultrasound velocity criteria for renal in-stent restenosis. J Vasc Surg. 2009;50(1):119–123.
12. Cooper CC, Murphy TP, Cutlip DE. et al. and CORAL Investigators CORAL Cardiovascular Outcomesin Renal Atherosclerotic Lesions. Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. New Engl J Med. 2014;370(1):13–22.
13. Drieghe B, Madaric J, Sarno G.et al. Assessment of renal artery stenosis: side-by-side comparison of angiography and duplex ultrasound with pressure gradient measurements. Eur Heart J. 2008;29:517–524.
14. Eklöf H, Ahlström H, Magnusson A. et al. A prospective comparison of duplex ultrasonography, captopril renography, MRA, and CTA in assessing renal artery stenosis. Acta Radiol. 2006;47(8):764–774.
15. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation. 2005;112(9):1362–1364.
16. García-Criado A, Gilabert R, Nicolau C. et al. Value of Doppler sonography for predicting clinical outcome after renal artery revascularization in atherosclerotic renal artery stenosis. J Ultrasound Med. 2005;24(12):1641–1647.
17. Greco BA, Breyer JA. Atherosclerotic ischemic renal disease. Am J Kidney Dis. 1997;29(2):167–187.
18. Hackam DG, Duong-Hua ML, Mamdani M. et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J. 2008;156(3):549–555.
19. Herrmann SMS, Textor SC. Diagnostic criteria for renovascular disease: where are we now? Nephrol Dial Transplant. 2012;27(7):2657–2663.
20. Hirsch AT, Haskal ZJ, Hertzer NR. et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) – summary of recommendations. J Vasc Interv Radiol. 2006;17(9):1383–1397.
21. Katritsis DG, Gersh BJ, Camm AJ. Clinical Cardiology: Current Practice Guidelines: updated edition. Oxford University Press 2016. 1008 p.
22. Leiner T, de Haan MW, Nelemans PJ. et al. Contemporary imaging techniques for the diagnosis of renal artery stenosis. Eur Radiol. 2005;15(11):2219–2229.
23. Levine GN, Gomes AS, Arai AE. et al. Safety of Magnetic Resonance Imaging in Patients With Cardiovascular Devices. Circulation. 2007;116:2878–2891.
24. Mailloux LU. Atherosclerotic ischemic renal vascular disease: do published outcomes justify the overzealous diagnostic approaches? Semin Nephrol. 2003;23(3):278–282.
25. Plouin PF. Stable patients with atherosclerotic renal artery stenosis should be treated first with medical management. Am J Kidney Dis. 2003;42(5):851–857.
26. Prasad S, Bannister K, Taylor J. Is magnetic resonance angiography useful in renovascular disease? Intern Med J. 2003;33(3):84–90.
27. Prince MR, Schoenberg SO, Ward JS. et al. Hemodynamically significant atherosclerotic renal artery stenosis: MR angiographic features. Radiology. 1997;205(1):128–136.
28. Radermacher J, Chavan A, Bleck J. et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. New Engl J Med. 2001;344(6):410–417.
29. Rountas C, Vlychou M, Vassiou K. et al. Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital substraction angiography. Ren Fail. 2007;29(3):295–302.
30. Safian RD, Madder RD. Refining the approach to renal artery revascularization. JACC Cardiovasc Interv. 2009;2(3):161–174.
31. Sahin S, Cimşit C, Andaç N. et al. Renal artery stenting in solitary functioning kidneys: technical and clinical results. Eur J Radiol. 2006;57(1):131–137.
32. Santos S, Leite LR, Tse TS. et al. Renal resistance index predicting outcome of renal revascularization for renovascular hypertension. Arq BrasCardiol. 2010;94(4):452–456.
33. Schäberle W, Leyerer L, Schierling W, Pfister K. Ultrasound diagnostics of renal artery stenosis. Stenosis criteria, CEUS and recurrent in-stent stenosis. Gefasschirurgie. 2016;21:4–13.
34.Shellock FG, Crues JV. MR Safety and the American College of Radiology White Paper. Am J Roentgenol. 2002;178(6):1349–1352.
35. Spyridopoulos TN, Kaziani K, Balanika AP. et al. Ultrasound as a first line screening tool for the detection of renal artery stenosis: a comprehensive review. Med Ultrason. 2010;12(3):228–232.
36. Tendera M, Aboyans V, Bartelink ML. 2011 ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J. 2011;32:2851–2906.
37. Vasbinder GB, Nelemans PJ, Kessels AG. et al. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med. 2001;135(6):401–411.
38. Vasbinder GB, Nelemans PJ, Kessels AG. et al. Accuracyofcomputedtomographicangiographyandmagneticresonanceangiographyfordiagnosingrenalarterystenosis. Ann Intern. Med. 2004;141(9):674–682.
39. Wheatley K, Ives N, Gray R, Kalra PA. et al. ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361(20):1953–1962.
40. White CJ, Jaff MR, Haskal ZJ. et al. Indications for renal arteriography at the time of coronaryarteriography: a science advisory from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Councilon Clinical Cardiology, and the Councilson Cardiovascular Radiology and Interventionand on Kidney in Cardiovascular Disease. Circulation. 2006;1140:1892–1895.

Ефективність та безпечність періопераційного застосування статинів при проведенні аортокоронарного шунтування

І.В. Шклянка, О.Й. Жарінов, К.О. Міхалєв, О.А. Єпанчінцева, Б.М. Тодуров

Література 

1. Lyakh YuE, Guryanov VG, Khomenko VN, Panchenko OA. Basics of Computer Biostatistics. Analysis of information in biology, medicine and pharmacy statistical package Medstat. Donetsk, 2006. 214 p. (in Russ.).
2. Todurov BM, Zharinov OYe, Okpanchintseva OA. et al. Paroxysmal atrial fibrillation early in postoperative aortic coronary artery bypass grafting. Ukr J Cardiol. 2011;2:96-101. (in Ukr.).
3. Auer J, Weber T, Berent R. et al. Postoperative atrial fibrillation independently predicts prolongation of hospital stay after cardiac surgery. Cardiovasc Surg. 2005;46:583-588.
4. Barakat AF, Saad M, Abuzaid A. et al. Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting. Ann Thorac Surg. 2016;101(2):818-825.
5. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Eur Cytokine Netw. 2008;19(2):99-103.
6. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg. 1999;15:394-400.
7. De Waal BA, Buise MP, Van Zundert AAJ. Perioperative statin therapy in patients at high risk for cardiovascular morbidity undergoing surgery. Br J Anaesth. 2015;114(1):44-52.
8. Eknoyan G, Lameire N. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Off J Intern Soc Nephrology. 2013;3(1):1-150.
9. Filion KB, Pilote L, Rahme E. et al. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery. J Card Surg. 2008;23:209-215.
10. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation. 2013;48:452-458.
11. Kang S, Liu Y, Liu X.B. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials. Clin Ther. 2013;35(8):1125-1136.
12. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter. 2012;2 (Suppl.):1-138.
13. Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database of Systematic Reviews. 2015;8. CD008493.
14. Kulik A, Ruel M, Jneid H. et al. American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131(10):927-964.
15. Landoni G, Casso G, Gallo M. et al. Perioperative statin therapy in cardiac surgery: a meta-analysis of randomized controlled trials. Critісаl Care. 2016;20:395.
16. Liakopoulos OJ, Choi YH, Haldenwang PL. et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients. Eur Heart J. 2008;29(12):1548-1559.
17. Loppnow H, Zhang L, Buerke M. et al. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med. 2011;15(4):994-1004.
18. Mills EJ, Wu P, Chong G. et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109-124.
19. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003.
20. Najmeddine E, Pibarot P, O’Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiacsurgery. J Amer Coll Cardiology. 2008;51(8):797-800.
21. Poldermans D, Bax JJ, Boersma E. et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009;30 (22):2769-2812.
22. Tandon V, Bano G, Khajuria V. et al. Pleiotropic effects of statins. Indian J Pharmacology. 2005;37(2):77-85.
23. Williams TM, Harken AH. Statins for surgical patients. Ann Surg. 2008;247:30-37.
24. Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac. Surg. 2014;46(4):517-592.
25. Zheng Z, Jayaram R, Jiang L. et al. Perioperative Rosuvastatin in Cardiac Surgery. New Engl J Med. 2016;374:1744-1753.

Показники ехокардіографії у хворих на атеросклероз периферичних артерій нижніх кінцівок залежно від поліморфізму T(–786)C промотора гена ендотеліальної NO-синтази

В.Й. Целуйко, О.Д. Ярова

Література 

1. Nechesova TA, Korobko IY, Kuznetsova NI. Remodeling of the left ventricle: pathogenesis and evaluation methods. Medicinskiie novosti. 2008;11:7-13. (in Russ.).
2. Parkhomenko ОМ, Lutai YаM, Irkin OI. Clinical and prognostic value of polymorphism of endothelial NO synthetase gene in patients with acute coronary syndromes. Emergency medicine. 2014;3(58):45-54. (in Russ.).
3. Recommendations for echocardiographic evaluation of left ventricular diastolic function. Recommendations of the Working Group on Functional Diagnostics of the Association of Cardiologists of Ukraine and the All-Ukrainian Association of Specialists in Echocardiography. 2016. webcardio.org. (in Ukr.).
4. Tsuleuko VYu, Yakovleva LM, Luchkov AB. Indicators of intracardiac hemodynamics in patients with coronary heart disease depending on the polymorphism of the T(-786)C promoter of the endothelial NO synthase gene. Emergency medicine. 2013;8(55): 99-104. (in Ukr.).
5. Bouisset F, Bongard V, Ruidavets JB. et al. Prognostic usefulness of clinical and subclinical peripheral arterial disease in men with stable coronary heart disease. Amer J Cardiology. 2012;110(2):197-202.
6. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Eur J Physiology. 2010;459:923-939.
7. Fowkes F, Rudan P, Aboyans V. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329-1340.
8. Fumihiko Kamezaki, Masato Tsutsui, Masao Takahashi et al. Plasma levels of nitric oxide metabolites are markedly reduced in normotensive men with electrocardiographically determined left ventricular hypertrophy. Hypertension. 2014;64:516-522.
9. Jiangping S, Zhe Z, Wei W. et al. Assessment of coronary artery stenosis by coronary angiography. Circulation. 2013;6:262-268.
10. Kablak-Ziembicka A, Przewlocki T, Pieniazek P. et al. The role of carotid intima-media thickness assessment in cardiovascular risk evaluation in patients with polyvascular atherosclerosis. Atherosclerosis. 2010;209(1):125-130.
11. Lang RM, Badano LP, Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J. 2015;16:233-271.
12. Mahmoodi K, Soltanpour M, Kamali K. Assessment of the role of plasma nitric oxide levels, T(–786)C genetic polymorphism, and gene expression levels of endothelial nitric oxide synthase in the development of coronary artery disease. Intern J Research Med Sciences. 2017;22:34.
13. Peach G, Griffin M, Jones K. et al. Diagnosis and management of peripheral arterial disease. Brit Med J. 2012;345:36-41.
14. REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. J Amer Med Association. 2010;304(12):1350-1357.
15. Salimi S, Naghavi A, Firoozrai M. Association of plasma nitric oxide concentration and endothelial nitric oxide synthase T(–786)C gene polymorphism in coronary artery disease. Pathophysiology. 2012;19(3):157-162.
16. Thygesen K, Alpert J, Jaffe A. et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-2203.
17. Tosaka A, Ishihara T, Iida O. et al. Angiographic evaluation and clinical risk factors of coronary artery disease in patients with peripheral artery disease. J Amer Coll Cardiology. 2014;63(12).
18. Ward P, Goonewardena S, Lammertin G. et al. Comparison of the frequency of abnormal cardiac findings by echocardiography in patients with and without peripheral arterial disease. Amer J Cardiology. 2007;99(4):499-503.

Гострий інфаркт міокарда з елевацією сегмента ST у пацієнта молодого віку із синдромом Барде – Бідля

І.М. Січкарук, О.В. Христюк, М.Є. Романів, О.А. Василькова, О.С. Карголь, М.М. Павелко, А.В. Ягенський

Література 

1. Zaremba YeH, Kyiak YuG, Solomenchuk TM. et al. Influence of occupational damages on changes in immune status in patients with acute myocardial infarction. Praktychna Medicina. 2004;10(3):41-43. (in Ukr.).
2. Zerbino DD, Solomenchuk TM, Skybchyk VA. Myocardial infarction in young patients: predictors and peculiarities of course. Ukr J Cardiol. 2004;4:89-94. (in Ukr.).
3. Zerbino DD, Solomenchuk TM, Skybchyk VA. Coronary artery disease and myocardial infarction in the young age: the role of xenobiotics (facts, hypotheses, comments). Ukr J Cardiol. 2003;1:14-20. (in Ukr.).
4. Malchevska TY. Coagulation risk factors and laboratory methods for their evaluation. Internal Medicine. 2007;6(6). (in Ukr.).
5. Bardet G. On congenital obesity syndrome with polydactyly and retinitis pigmentosa (a contribution to the study of clinical forms of hypophyseal obesity). Obes Res. 1995;3:387-399.
6. Beales PL, Elcioglu N, Woolf AS. et al. New criteria for improved diagnosis of Bardet-Biedl Syndrome: results of a population survey. J. Med. Genet. 1999;36:437-446.
7. Benzinou1 M, Walley A, Lobbens S. et al. Bardet-Biedl Syndrome Gene Variants Are Associated With Both Childhood and Adult Common Obesity in French Caucasians. Diabetes. 2006;55 (10):2876–2882.
8. Biedl A. A pair of siblings with adiposo-genital dystrophy. Obes Res. 1995;3:404.
9. Brscic E, Bergerone S, Gagnor A. et al. Acute myocardial infarction in young adults. Am Heart J. 2000;139 (6).
10. Forsythe E, Beales PL. Bardet–Biedl syndrome. Eur. J. Human Genetics. 2013;21:8-13.
11. Grace C, Beales P, Summerbell C. et al. Energy metabolism in Bardet-Biedl syndrome. Int J Obes Relat Metab Disord. 2003;27:1319-1324.
12. Green JS, Parfrey PS, Harnett JD. et al. The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. New Engl J Med. 1989;321:1002–1009.
13. Incalcaterra E, Caruso M. et al. Myocardial infarction in young adults: risk factors, clinical characteristics and prognosis according to our experience. Clin Ter. 2013;164 (2):e77–82.
14. Laurence JZ, Moon RC. Four cases of ‘retinitis pigmentosa’ occurring in the same family, and accompanied by general imperfections of development. Obes Res. 1995;3:400–403.
15. Moore SJ, Green JS, Fan Y. et al. Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study. Am J Med Genet. 2005;132:352–360.
16. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384 (9943):626–635.
17. Yunyun W, Tong L, Yingwu L. Analysis of risk factors of ST-segment elevation myocardial infarction in young patients. BMC Cardiovascular Disorders. 2014;14:179.

Кавернозная гемангиома митрального клапана – редкая опухоль сердца. Случай из практики

Р.М. Витовский, А.А. Пищурин, М.Н. Сердюк, В.В. Исаенко, В.Ф. Онищенко

Литература 

1. Amano J, Nakayama J, Yoshimura Y, Ikeda U. Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences. Gen Thorac Cardiovasc Surg. 2013:61(8):435-447.
2. Brizard C, Latremouille C, Jebara VA. Cardiac hemangiomas. Ann Thorac Surg. 1993:56(2):390-394.
3. Bruce CJ. Cardiac tumours: diagnosis and management. Heart. 2011:97(2):151-160.
4. Isbitan A, Shaaban H, Qaqa A. et al. Cavernous hemangioma of the mitral valve in an adult male patient successfully treated with surgical resection: a case report. J Heart Valve Dis. – 2014:23(5):662-664.
5. Lapenna E, De Bonis M, Torracca L. et al. Cavernous hemangioma of the tricuspid valve: minimally invasive surgical resection. Ann Thorac Surg. 2003:76(6):2097-2099.
6. Eftychiou C, Antoniades L. Cardiac hemangioma in the left ventricle and brief review of the literature. J Cardiovasc Med. 2009:10(7):565-567.
7. Matsumoto Y, Watanabe G, Endo M, Sasaki H. Surgical treatment of a cavernous hemangioma of the left atrial roof. Eur J Cardiothorac Surg. 2001:20(3):633-635.
8. McAllister H. Tumors of the heart and pericardium. Cardiovascular pathology. Ed. M.D. Silver. New York: Churchill Livingstone, 1983:909-943.
9. Thomas JE, Eror AT, Kenney M, Caravalho JJr. Asymptomatic right atrial cavernous hemangioma: a case report and review of the literature. Cardiovasc Pathol. 2004;13(6):341-344.
10. Vander Salm T.J. Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg. 2000;12(2):89-100.
11. Yaganti V, Patel S, Yaganti S, Victor M. Cavernous hemangioma of the mitral valve: a case report and review of literature. J Cardiovasc Med (Hagerstown). 2009:10(5):420-422.

Періопераційна медикаментозна терапія в кардіохірургічній практиці в дорослих: клінічні рекомендації Європейського товариства кардіоторакальних хірургів 2017 року

M. Sousa-Uva, S. Head, M. Milojevic, J.-P. Collet, G. Landoni, M. Castella, J. Dunning, T. Gudbjartsson, N. Linker, E. Sandoval, M. Thielmann, A. Jeppsson, U. Landmesser

Література 

1. Sousa-Uva M, Head SJ, Thielmann M, Cardillo G, Benedetto U, Czerny M et al. Methodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. Eur J Cardiothorac Surg 2015;48:809–16.
2. Kulik A, Desai NR, Shrank WH, Antman EM, Glynn RJ, Levin R et al. Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial. Circulation 2013;128:S219–25.
3. Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K et al. Efficacy of chronic b-blocker therapy for secondary prevention on long-term out- comes after coronary artery bypass grafting surgery. Circulation 2015; 131:2194–201.
4. Milojevic M, Head SJ, Parasca CA, Serruys PW, Mohr FW, Morice MC et al. Causes of death following PCI versus CABG in complex CAD: 5- year follow-up of SYNTAX. J Am Coll Cardiol 2016;67:42–55.
5. Hlatky MA, Solomon MD, Shilane D, Leong TK, Brindis R, Go AS. Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention. J Am Coll Cardiol 2013;61:295–301.
6. Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA et al. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J 2016;37:3576–84.
7. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014;46:517–92.
8. Niebauer J. Is there a role for cardiac rehabilitation after coronary artery bypass grafting? Treatment after coronary artery bypass surgery remains incomplete without rehabilitation. Circulation 2016;133:2529–37.
9. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A et al. Coronary artery bypass graft surgery versus percutaneous coron- ary intervention in patients with three-vessel disease and left main cor- onary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629–38.
10. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015;372:1204–12.
11. Iqbal J, Zhang YJ, Holmes DR, Morice MC, Mack MJ, Kappetein AP et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary interven- tion or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation 2015;131:1269–77.
12. Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD et al. Influence of practice patterns on outcome among countries en- rolled in the SYNTAX trial: 5-year results between percutaneous coron- ary intervention and coronary artery bypass grafting. Eur J Cardiothorac Surg 2017;52:445–53.
13. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008;34:73–92.
14. Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR et al. The Society of Thoracic Surgeons practice guideline series: blood glucose management during adult cardiac surgery. Ann Thorac Surg 2009;87:663–9.
15. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS et al. Secondary prevention after coronary artery bypass graft surgery: a sci- entific statement from the American Heart Association. Circulation 2015;131:927–64.
16. Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. ESC/ EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg 2017;52:616–64.
17. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016;50:e1–88.
18. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–867.
19. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.
20. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999–3058.
21. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients pre- senting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315.
22. Pagano D, Milojevic M, Meesters MI, Benedetto U, Bolliger D, von Heymann C. 2017 EACTS/EACTA Guidelines on patient blood manage- ment for adult cardiac surgery. The task force on patient blood manage- ment for adult cardiac surgery of the European Association for Cardio- Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA). Eur J Cardiothorac Surg 2018; 53:79–111.
23. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocar- dial infarction, and stroke in high risk patients. Br Med J 2002;324:71–86.
24. Hastings S, Myles P, McIlroy D. Aspirin and coronary artery surgery: a systematic review and meta-analysis. Br J Anaesth 2015;115:376–85.
25. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T et al. Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med 2016;374:728–37.
26. Deja MA, Kargul T, Domaradzki W, Sta˛cel T, Mazur W, Wojakowski W et al. Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg 2012;144:204–9.
27. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005;130:791–6.
28. Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial in- farction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008;29:1057–71.
29. Nenna A, Spadaccio C, Prestipino F, Lusini M, Sutherland FW, Beattie GW et al. Effect of preoperative aspirin replacement with enoxaparin in patients undergoing primary isolated on-pump coronary artery bypass grafting. Am J Cardiol 2016;117:563–70.
30. Hansson EC, Shams Hakimi C, Astrom-Olsson K, Hesse C, Wallen H, Dellborg M et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014;112:570–5.
31. Martin AC, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol 2016;33:361–7.
32. Zisman E, Erport A, Kohanovsky E, Ballagulah M, Cassel A, Quitt M et al. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients. Eur J Anaesthesiol 2010;27:617–23.
33. Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309–17.
34. Musleh G, Dunning J. Does aspirin 6 h after coronary artery bypass grafting optimise graft patency? Interact CardioVasc Thorac Surg 2003;2:413–5.
35. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syn- dromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
36. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syn- dromes. N Engl J Med 2009;361:1045–57.
37. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute cor- onary syndromes. N Engl J Med 2007;357:2001–15.
38. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933–44.
39. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coron- ary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202–8.
40. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672–84.
41. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coron- ary artery bypass grafting cohort: risk-adjusted retrospective data ana- lysis. J Am Coll Cardiol 2012;60:388–96.
42. Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 2016;37:189–97.
43. Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related bleeding complications in pa- tients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg 2016;50:849–56.
44. Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrel-associated bleeding and related complications in patients undergoing coronary ar- tery bypass grafting. Pharmacotherapy 2008;28:376–92.
45. Purkayastha S, Athanasiou T, Malinovski V, Tekkis P, Foale R, Casula R et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 2006;92:531–2.
46. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 2012;94:1761–81.
47. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 2018;53:34–78.
48. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265–74.
49. Qamar A, Bhatt DL. Current status of data on cangrelor. Pharmacol Ther 2016;159:102–9.
50. Wallentin L. P2Y(12) inhibitors: differences in properties and mechan- isms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964–77.
51. Gherli R, Mariscalco G, Dalen M, Onorati F, Perrotti A, Chocron S et al. Safety of preoperative use of ticagrelor with or without aspirin com- pared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016; 1:921–8.
52. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120:2577–85.
53. Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antipla- telet responses. J Thromb Haemost 2011;9:1730–7.
54. Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospect- ive observational study. Br J Anaesth 2016;117:309–15.
55. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative ana- lysis on the role of platelet reactivity for risk stratification after percutan- eous coronary intervention. Eur Heart J 2015;36:1762–71.
56. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100–9.
57. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C et al. Platelet function monitoring to adjust antiplatelet ther- apy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016;388:2015–22.
58. Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel respon- siveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010;56:1994–2002.
59. Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011;91:123–9.
60. Ranucci M, Colella D, Baryshnikova E, Di Dedda U, Hemmings HC; Surgical and Clinical Outcome Research (SCORE) Group. Effect of pre- operative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 2014;113:970–6.
61. Mahla E, Prueller F, Farzi S, Pregartner G, Raggam RB, Beran E et al. Does platelet reactivity predict bleeding in patients needing urgent cor- onary artery bypass grafting during dual antiplatelet therapy? Ann Thorac Surg 2016;102:2010–7.
62. Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET- CABG) study. Circ Cardiovasc Interv 2012;5:261–9.
63. Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M et al. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg 2015;15:112.
64. Deo SV, Dunlay SM, Shah IK, Altarabsheh SE, Erwin PJ, Boilson BA et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg 2013;28:109–16.
65. van Diepen S, Fuster V, Verma S, Hamza TH, Siami FS, Goodman SG et al. Dual antiplatelet therapy versus aspirin monotherapy in diabetics with multivessel disease undergoing CABG: FREEDOM insights. J Am Coll Cardiol 2017;69:119–27.
66. Savonitto S, D’Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010;104:285–91.
67. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234S–64S.
68. Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve long-term outcome with abcixi- mab GP IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibition in STENTing. Ann Thorac Surg 2000;70:516–26.
69. De Carlo M, Maselli D, Cortese B, Ciabatti N, Gistri R, Levantino M et al. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibi- tors. Int J Cardiol 2008;123:229–33.
70. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD et al. Pacemaker or defibrillator surgery without interruption of anticoagula- tion. N Engl J Med 2013;368:2084–93.
71. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–507.
72. Faraoni D, Levy JH, Albaladejo P, Samama CM; Groupe d’Inte´r^et en He´ mostase Pe´ riope´ ratoire. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care 2015;19:203.
73. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS et al. Perioperative bridging anticoagulation in patients with atrial fibril- lation. N Engl J Med 2015;373:823–33.
74. Jones HU, Muhlestein JB, Jones KW, Bair TL, Lavasani F, Sohrevardi M et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation 2002;106(12 Suppl 1):I19–22.
75. Gellatly RM, Leet A, Brown KE. Fondaparinux: an effective bridging strat- egy in heparin-induced thrombocytopenia and mechanical circulatory support. J Heart Lung Transplant 2014;33:118.
76. O’Donnell MJ, Kearon C, Johnson J, Robinson M, Zondag M, Turpie I et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007;146:184–7.
77. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270–382.
78. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)—March 2013. Arch Cardiovasc Dis 2013;106:382–93.
79. Levy JH, Spyropoulos AC, Samama CM, Douketis J. Direct oral anticoagu- lants: new drugs and new concepts. JACC Cardiovasc Interv 2014;7:1333–51.
80. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2013;111:189–98.
81. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373:511–20.
82. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131–41.
83. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24.
84. Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S, Douketis J, Jacobson A et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 2008;102:883–9.
85. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319–26.
86. Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A et al. Clinical outcomes with unfractionated heparin or low- molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4:1246–52.
87. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658–63.
88. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anti- coagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007;167:117–24.
89. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–41.
90. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the preven- tion of prosthetic heart valve thromboembolism: a prospective random- ized clinical trial. Circulation 1985;72:1059–63.
91. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1–44.
92. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003;89:527–30.
93. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular- weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 2006;113:564–9.
94. Iung B, Rodes-Cabau J. The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. Eur Heart J 2014;35:2942–9.
95. Grzymala-Lubanski B, Svensson PJ, Renlund H, Jeppsson A, Sj€alander A. Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. Heart 2017;103:198–203
96. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R et al. Self-monitoring of oral anticoagulation: systematic review and meta- analysis of individual patient data. Lancet 2012;379:322–34.
97. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C et al. Self-monitoring and self-management of oral anticoa- gulation. Cochrane Database Syst Rev 2016;7:CD003839.
98. Head SJ, Celik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J 2017; doi:10.1093/eurheartj/ehx141.
99. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206–14.
100. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433–41.
101. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS et al. Early anticoagulation of bioprosthetic aortic valves in older pa- tients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012;60:971–7.
102. Merie C, Kober L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complica- tions, and bleeding. JAMA 2012;308:2118–25.
103. Rafiq S, Steinbru¨chel DA, Lilleør NB, Møller CH, Lund JT, Thiis JJ et al. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017;150:104–10.
104. Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE et al. Timing, predictive factors, and prognostic value of cere- brovascular events in a large cohort of patients undergoing transcath- eter aortic valve implantation. Circulation 2012;126:3041–53.
105. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, de Backer O et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 2015;373:2015–24.
106. Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, Nombela-Franco L, Cheema A, Kefer J et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2016;9:1706–17.
107. Steinberg BA, Zhao Y, He X, Hernandez AF, Fullerton DA, Thomas KL et al. Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: in- sights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. Clin Cardiol 2014;37:7–13.
108. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P et al. Atrial fibrillation after isolated coronary surgery affects late sur- vival. Circulation 2008;118:1612–8.
109. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrilla- tion in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg 2010;37:1353–9.
110. Dunning J, Treasure T, Versteegh M, Nashef SA, Audit E, Guidelines C. Guidelines on the prevention and management of de novo atrial fibrilla- tion after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006;30:852–72.
111. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013;1:CD003611.
112. Sear JW, Foex P. Recommendations on perioperative beta-blockers: differing guidelines: so what should the clinician do? Br J Anaesth 2010;104:273–5.
113. Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-analysis. Pacing Clin Electrophysiol 2013;36:1017–23.
114. Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010;12:356–63.
115. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E et al. N-3 Fatty acids for the prevention of atrial fibrillation after coron- ary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723–8.
116. Miller S, Crystal E, Garfinkle M, Lau C, Lashevsky I, Connolly SJ. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart 2005;91:618–23.
117. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. Scand Cardiovasc J Suppl 2013; 47:2–10.
118. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652–9.
119. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med 2016;374:1911–21.
120. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 2015; 36:1831–8.
121. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014;312:616–22.
122. Anderson E, Dyke C, Levy JH. Anticoagulation strategies for the man- agement of postoperative atrial fibrillation. Clin Lab Med 2014;34: 537–61.
123. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
124. Seeger J, Gonska B, Rodewald C, Rottbauer W, Wo¨ hrle J. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv 2017;10:66–74.
125. Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D et al. Perioperative beta-blockers for preventing surgery-related mortal- ity and morbidity. Cochrane Database Syst Rev 2014;9:CD004476.
126. Brinkman W, Herbert MA, O’Brien S, Filardo G, Prince S, Dewey T et al. Preoperative beta-blocker use in coronary artery bypass grafting sur- gery: national database analysis. JAMA Intern Med 2014;174:1320–7.
127. Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O’Brien B, Carroll S et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. Am Heart J 2003; 145:226–32.
128. White CM, Caron MF, Kalus JS, Rose H, Song J, Reddy P et al. Intravenous plus oral amiodarone, atrial septal pacing, or both strat- egies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II). Circulation 2003; 108:II200–6.
129. Mitchell LB, Exner DV, Wyse DG, Connolly CJ, Prystai GD, Bayes AJ et al. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair: PAPABEAR: a randomized controlled trial. JAMA 2005;294:3093–100.
130. Lee JK, Klein GJ, Krahn AD, Yee R, Zarnke K, Simpson C et al. Rate- control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results. Card Electrophysiol Rev 2003; 7:178–84.
131. Hagens VE, Van Gelder IC, Crijns HJ. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. Card Electrophysiol Rev 2003;7:118–21.
132. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071–104.
133. Al-Khatib SM, Hafley G, Harrington RA, Mack MJ, Ferguson TB, Peterson ED et al. Patterns of management of atrial fibrillation complicating cor- onary artery bypass grafting: results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. Am Heart J 2009;158:792–8.
134. Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K et al. Impact of the CHA2DS2-VASc score on anticoagulation recom- mendations for atrial fibrillation. Am J Med 2012;125:603.e1–6.
135. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–62.
136. Bhatia M, Arora H, Kumar PA. Pro: ACE inhibitors should be continued perioperatively and prior to cardiovascular operations. J Cardiothorac Vasc Anesth 2016;30:816–9.
137. Disque A, Neelankavil J. Con: ACE inhibitors should be stopped prior to cardiovascular surgery. J Cardiothorac Vasc Anesth 2016;30:820–2.
138. Mangieri A. Renin-angiotensin system blockers in cardiac surgery. J Crit Care 2015;30:613–8.
139. Zou Z, Yuan HB, Yang B, Xu F, Chen XY, Liu GJ et al. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 re- ceptor blockers for preventing mortality and morbidity in adults. Cochrane Database Syst Rev 2016;1:CD009210.
140. Bertrand M, Godet G, Meersschaert K, Brun L, Salcedo E, Coriat P. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg 2001;92:26–30.
141. Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D et al. Effects of angiotensin-converting enzyme inhibition in low-risk pa- tients early after coronary artery bypass surgery. Circulation 2008; 117:24–31.
142. Zhang Y, Ma L. Effect of preoperative angiotensin-converting enzyme inhibitor on the outcome of coronary artery bypass graft surgery. Eur J Cardiothorac Surg 2015;47:788–95.
143. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD et al. Management of vasodilatory shock after cardiac surgery: iden- tification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973–80.
144. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000;15:347–53.
145. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members ap- pointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507–20.
146. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G et al. European Society of Hypertension practice guidelines for ambulatory blood pres- sure monitoring. J Hypertens 2014;32:1359–66.
147. Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2004; 4:CD003611.
148. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP et al. Valsartan, captopril, or both in myocardial infarction compli- cated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906.
149. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting- enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71.
150. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–66.
151. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001;87:542–6.
152. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R et al. Preoperative use of angiotensin-converting enzyme inhibitors/angioten- sin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 2008;3:1266–73.
153. Savarese G, Costanzo P, Cleland JGF, Vassallo E, Ruggiero D, Rosano G et al. A meta-analysis reporting effects of angiotensin-converting en- zyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131–42.
154. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17.
155. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symp- toms. N Engl J Med 2011;364:11–21.
156. Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS. Combining neuroendocrine inhibitors in heart failure: reflections on safety and effi- cacy. Am J Med 2007;120:1090.e1–8.
157. Pitt B, Pedro Ferreira J, Zannad F. Mineralocorticoid receptor antagon- ists in patients with heart failure: current experience and future perspec- tives. Eur Heart J Cardiovasc Pharmacother 2017;3:48–57.
158. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293–302.
159. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ven- tricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669–77.
160. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–35.
161. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
162. Chan AY, McAlister FA, Norris CM, Johnstone D, Bakal JA, Ross DB. Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery. J Thorac Cardiovasc Surg 2010;140:182–7, 7.e1.
163. ten Broecke PW, De Hert SG, Mertens E, Adriaensen HF. Effect of pre- operative beta-blockade on perioperative mortality in coronary surgery. Br J Anaesth 2003;90:27–31.
164. Daumerie G, Fleisher LA. Perioperative beta-blocker and statin therapy. Curr Opin Anaesthesiol 2008;21:60–5.
165. Blessberger H, Kammler J, Steinwender C. Perioperative use of beta- blockers in cardiac and noncardiac surgery. JAMA 2015;313:2070–1.
166. Carl M, Alms A, Braun J, Dongas A, Erb J, Goetz A et al. S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system. Ger Med Sci 2010;8:Doc12.
167. Sjoland H, Caidahl K, Lurje L, Hjalmarson A, Herlitz J. Metoprolol treatment for two years after coronary bypass grafting: effects on exercise capacity and signs of myocardial ischaemia. Br Heart J 1995;74:235–41.
168. Puymirat E, Riant E, Aissoui N, Soria A, Ducrocq G, Coste P et al. b blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. Br Med J 2016; 354:i4801.
169. Booij HG, Damman K, Warnica JW, Rouleau JL, van Gilst WH, Westenbrink BD. b-blocker therapy is not associated with reductions in angina or cardiovascular events after coronary artery bypass graft sur- gery: insights from the IMAGINE Trial. Cardiovasc Drugs Ther 2015;29: 277–85.
170. Lin T, Hasaniya NW, Krider S, Razzouk A, Wang N, Chiong JR. Mortality reduction with beta-blockers in ischemic cardiomyopathy patients undergoing coronary artery bypass grafting. Congest Heart Fail 2010;16: 170–4.
171. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13.
172. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550–60.
173. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–90.
174. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7.
175. Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B et al. Benefits of b blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. Br Med J 2013; 346:f55.
176. Ferguson TB Jr, Coombs LP, Peterson ED; Society of Thoracic Surgeons National Adult Cardiac Surgery Database. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA 2002;287:2221–7.
177. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary sur- gery: a randomized trial. J Thorac Cardiovasc Surg 2008;136:1541–8.
178. Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2015;8:CD008493.
179. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med 2016;374:1744–53.
180. Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG et al. High-dose perioperative atorvastatin and acute kidney injury follow- ing cardiac surgery. A randomized clinical trial. JAMA 2016;315:877–88.
181. Bellomo R. Perioperative statins in cardiac surgery and acute kidney in- jury. JAMA 2016;315:873–4.
182. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol 2008; 51:1938–43.
183. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012–22.
184. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–22.
185. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489–99.
186. Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in pa- tients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 2016;37:536–45.
187. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875–84.
188. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–74.
189. Cholesterol Treatment Trialists’ Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L et al. Efficacy and safety of LDL- lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385:1397–405.
190. Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol 2016;4:403–10.
191. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-ana- lysis. Ann Intern Med 2015;163:40–51.
192. Filsoufi F, Rahmanian PB, Castillo JG, Scurlock C, Legnani PE, Adams DH. Predictors and outcome of gastrointestinal complications in patients undergoing cardiac surgery. Ann Surg 2007;246:323–9.
193. van der Voort PH, Zandstra DF. Pathogenesis, risk factors, and incidence of upper gastrointestinal bleeding after cardiac surgery: is specific prophylaxis in routine bypass procedures needed? J Cardiothorac Vasc Anesth 2000;14:293–9.
194. Shin JS, Abah U. Is routine stress ulcer prophylaxis of benefit for patients undergoing cardiac surgery? Interact CardioVasc Thorac Surg 2012; 14:622–8.
195. Hata M, Shiono M, Sekino H, Furukawa H, Sezai A, Iida M et al. Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery. Circ J 2005;69:331–4.
196. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acidsuppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310–9.
197. Othman F, Crooks CJ, Card TR. Community acquired pneumonia inci- dence before and after proton pump inhibitor prescription: population based study. Br Med J 2016;355:i5813.
198. Patel AJ, Som R. What is the optimum prophylaxis against gastrointes - tinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists, or proton-pump inhibitors? Interact CardioVasc Thorac Surg 2013;16:356–60.
199. Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 2005;3:129–40.
200. Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 2008; 29:2592–600.
201. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:1243–53.
202. Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 2012;308:1761–7.
203. Dieleman JM, Van Dijk D. Corticosteroids for cardiac surgery: a summary of two large randomised trials. Neth J Crit Care 2016;24:6–10.
204. Liu MM, Reidy AB, Saatee S, Collard CD. Perioperative steroid management: approaches based on current evidence. Anesthesiology 2017; 127:166–72.
205. Fowler VG, O’Brien SM, Muhlbaier LH, Corey GR, Ferguson TB, Peterson ED. Clinical predictors of major infections after cardiac surgery. Circulation 2005;112(9 suppl):I358–65.
206. Gelijns AC, Moskowitz AJ, Acker MA, Argenziano M, Geller NL, Puskas JD et al. Management practices and major infections after cardiac sur- gery. J Am Coll Cardiol 2014;64:372–81.
207. Kowalewski M, Pawliszak W, Zaborowska K, Navarese EP, Szwed KA, Kowalkowska ME et al. Gentamicin-collagen sponge reduces the risk of sternal wound infections after heart surgery: meta-analysis. J Thorac Cardiovasc Surg 2015;149:1631–40.e1–6.
208. Zelenitsky SA, Ariano RE, Harding GK, Silverman RE. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraopera- tive antibiotic concentrations and efficacy. Antimicrob Agents Chemother 2002;46:3026–30.
209. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989;106:750–6; discussion 6–7.
210. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010;375:248–51.
211. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007;27:1081–91.
212. Tamayo E, Gualis J, Florez S, Castrodeza J, Eiros Bouza JM, Alvarez FJ. Comparative study of single-dose and 24-hour multiple-dose antibiotic prophylaxis for cardiac surgery. J Thorac Cardiovasc Surg 2008; 136:1522–7.
213. Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta- analysis. Ann Surg 2011;254:48–54.
214. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000; 101:2916–21.
215. Bratzler DW, Houck PM, Richards C, Steele L, Dellinger EP, Fry DE et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005; 140:174–82.
216. Sandoe JA, Kumar B, Stoddart B, Milton R, Dave J, Nair UR et al. Effect of extended perioperative antibiotic prophylaxis on intravascular catheter colonization and infection in cardiothoracic surgery patients. J Antimicrob Chemother 2003;52:877–9.
217. Niederhauser U, Vogt M, Vogt P, Genoni M, Kunzli A, Turina MI. Cardiac surgery in a high-risk group of patients: is prolonged postopera- tive antibiotic prophylaxis effective? J Thorac Cardiovasc Surg 1997; 114:162–8.
218. Conte JE Jr, Cohen SN, Roe BB, Elashoff RM. Antibiotic prophylaxis and cardiac surgery. A prospective double-blind comparison of single-dose versus multiple-dose regimens. Ann Intern Med 1972;76:943–9.
219. Trent Magruder J, Grimm JC, Dungan SP, Shah AS, Crow JR, Shoulders BR et al. Continuous intraoperative cefazolin infusion may reduce surgi- cal site infections during cardiac surgical procedures: a propensity- matched analysis. J Cardiothorac Vasc Anesth 2015;29:1582–7.
220. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an ad- visory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38:1706–15.
221. Scher KS. Studies on the duration of antibiotic administration for surgi- cal prophylaxis. Am Surg 1997;63:59–62.
222. Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does intraoperative blood loss affect antibiotic serum and tissue concentrations? Arch Surg 1996;131:1165–71; discussion 71–2.
223. Lanckohr C, Horn D, Voeller S, Hempel G, Fobker M, Welp H et al. Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac sur- gery. J Thorac Cardiovasc Surg 2016;152:603–10.
224. Gardlund B, Bitkover CY, Vaage J. Postoperative mediastinitis in cardiac surgery—microbiology and pathogenesis. Eur J Cardiothorac Surg 2002; 21:825–30.
225. Gudbjartsson T, Jeppsson A, Sjogren J, Steingrimsson S, Geirsson A, Friberg O et al. Sternal wound infections following open heart surgery— a review. Scand Cardiovasc J 2016;50:341–8.
226. Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM et al. New WHO recommendations on preoperative measures for surgi- cal site infection prevention: an evidence-based global perspective. Lancet Infect Dis 2016;16:e276–87.
227. Bode LGM, Kluytmans JAJW, Wertheim HFL, Bogaers D, Vandenbroucke- Grauls CMJE, Roosendaal R et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010;362:9–17.
228. Sisto T, Laurikka J, Tarkka MR. Ceftriaxone vs cefuroxime for infection prophylaxis in coronary bypass surgery. Scand J Thorac Cardiovasc Surg 1994;28:143–8.
229. Nooyen SM, Overbeek BP, Brutel de la Riviere A, Storm AJ, Langemeyer JJ. Prospective randomised comparison of single-dose versus multiple- dose cefuroxime for prophylaxis in coronary artery bypass grafting. Eur J Clin Microbiol Infect Dis 1994;13:1033–7.
230. Kriaras I, Michalopoulos A, Turina M, Geroulanos S. Evolution of anti- microbial prophylaxis in cardiovascular surgery. Eur J Cardiothorac Surg 2000;18:440–6.
231. Lador A, Nasir H, Mansur N, Sharoni E, Biderman P, Leibovici L et al. Antibiotic prophylaxis in cardiac surgery: systematic review and meta- analysis. J Antimicrob Chemother 2012;67:541–50.
232. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than beta-lactam agents for pre- vention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis 2004;38:1357–63.
233. Cunha BA. Antibiotic selection in the penicillin-allergic patient. Med Clin North Am 2006;90:1257–64.
234. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, Farinotti R. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992;36:2539–41.
235. Finkelstein R, Rabino G, Mashiah T, Bar-El Y, Adler Z, Kertzman V et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the set- ting of a high prevalence of methicillin-resistant staphylococcal infec- tions. J Thorac Cardiovasc Surg 2002;123:326–32.
236. Blumenthal KG, Shenoy ES, Varughese CA, Hurwitz S, Hooper DC, Banerji A. Impact of a clinical guideline for prescribing antibiotics to in- patients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol 2015;115:294–300.e2.
237. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol 2014;133:790–6.
238. Frigas E, Park MA, Narr BJ, Volcheck GW, Danielson DR, Markus PJ et al. Preoperative evaluation of patients with history of allergy to penicillin: comparison of 2 models of practice. Mayo Clin Proc 2008;83:651–62.
239. Anderson DJ, Podgorny K, Berr'ıos-Torres SI, Bratzler DW, Dellinger EP, Greene L et al. Strategies to prevent surgical site infections in Acute Care Hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:605–27.
240. Zangrillo A, Landoni G, Fumagalli L, Bove T, Bellotti F, Sottocorna O et al. Methicillin-resistant Staphylococcus species in a cardiac surgical intensive care unit: a 5-year experience. J Cardiothorac Vasc Anesth 2006;20:31–7.
241. Bull AL, Worth LJ, Richards MJ. Impact of vancomycin surgical antibiotic prophylaxis on the development of methicillin-sensitive Staphylococcus aureus surgical site infections: report from Australian Surveillance Data (VICNISS). Ann Surg 2012;256:1089–92.
242. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992;326:281–6.
243. Steinberg JP, Braun BI, Hellinger WC, Kusek L, Bozikis MR, Bush AJ et al. Timing of antimicrobial prophylaxis and the risk of surgical site infec- tions: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg 2009;250:10–6.
244. van Kasteren ME, Mannien J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important fac- tor. Clin Infect Dis 2007;44:921–7.
245. Weber WP, Marti WR, Zwahlen M, Misteli H, Rosenthal R, Reck S et al. The timing of surgical antimicrobial prophylaxis. Ann Surg 2008; 247:918–26.
246. Garey KW, Dao T, Chen H, Amrutkar P, Kumar N, Reiter M et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother 2006;58:645–50.
247. Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic oper- ations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992;104:590–9.
248. Vuorisalo S, Pokela R, Syrjala H. Is single-dose antibiotic prophylaxis sufficient for coronary artery bypass surgery? An analysis of peri- and post- operative serum cefuroxime and vancomycin levels. J Hosp Infect 1997; 37:237–47.
249. Lin MH, Pan SC, Wang JL, Hsu RB, Lin Wu FL, Chen YC et al. Prospective randomized study of efficacy of 1-day versus 3-day antibiotic prophy- laxis for preventing surgical site infection after coronary artery bypass graft. J Formos Med Assoc 2011;110:619–26.
250. Gupta A, Hote MP, Choudhury M, Kapil A, Bisoi AK. Comparison of 48 hand 72 h of prophylactic antibiotic therapy in adult cardiac surgery: a randomized double blind controlled trial. J Antimicrob Chemother 2010;65:1036–41.
251. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis 2001; 7:828–31.
252. Krivoy N, Yanovsky B, Kophit A, Zaher A, Bar-El Y, Adler Z et al. Vancomycin sequestration during cardiopulmonary bypass surgery. J Infect 2002;45:90–5.
253. Fellinger EK, Leavitt BJ, Hebert JC. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. Ann Thorac Surg 2002; 74:1187–90.
254. Mastoraki S, Michalopoulos A, Kriaras I, Geroulanos S. Cefuroxime as antibiotic prophylaxis in coronary artery bypass grafting surgery. Interact CardioVasc Thorac Surg 2007;6:442–6.
255. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aur- eus bacteremia. J Clin Microbiol 2004;42:2398–402.
256. Uhlig C, Bluth T, Schwarz K, Deckert S, Heinrich L, De Hert S et al. Effects of volatile anesthetics on mortality and postoperative pulmonary and other complications in patients undergoing surgery: a systematic review and meta-analysis. Anesthesiology 2016;124:1230–45.
257. Landoni G, Greco T, Biondi-Zoccai G, Nigro Neto C, Febres D, Pintaudi M et al. Anaesthetic drugs and survival: a Bayesian network meta- analysis of randomized trials in cardiac surgery. Br J Anaesth 2013; 111:886–96.
258. Landoni G, Isella F, Greco M, Zangrillo A, Royse CF. Benefits and risks of epidural analgesia in cardiac surgery. Br J Anaesth 2015;115:25–32.
259. Bignami E, Greco T, Barile L, Silvetti S, Nicolotti D, Fochi O et al. The ef- fect of isoflurane on survival and myocardial infarction: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2013; 27:50–8.
260. Bignami E, Biondi-Zoccai G, Landoni G, Fochi O, Testa V, Sheiban I et al. Volatile anesthetics reduce mortality in cardiac surgery. J Cardiothorac Vasc Anesth 2009;23:594–9.
261. De Hert S, Vlasselaers D, Barbe R, Ory JP, Dekegel D, Donnadonni R et al. A comparison of volatile and non volatile agents for cardioprotec- tion during on-pump coronary surgery. Anaesthesia 2009;64:953–60.
262. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus sevoflurane anesthesia on outcome in 10, 535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 2007;21:664–71.
263. Landoni G, Biondi-Zoccai GG, Zangrillo A, Bignami E, D’Avolio S, Marchetti C et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007;21:502–11.
264. Likhvantsev VV, Landoni G, Levikov DI, Grebenchikov OA, Skripkin YV, Cherpakov RA. Sevoflurane versus total intravenous anesthesia for iso- lated coronary artery bypass surgery with cardiopulmonary bypass: a randomized trial. J Cardiothorac Vasc Anesth 2016;30:1221–7.
265. Mazzeffi M, Khelemsky Y. Poststernotomy pain: a clinical review. J Cardiothorac Vasc Anesth 2011;25:1163–78.
266. Gelinas C. Management of pain in cardiac surgery ICU patients: have we improved over time? Intensive Crit Care Nurs 2007;23:298–303.
267. Schelling G, Richter M, Roozendaal B, Rothenhausler HB, Krauseneck T, Stoll C et al. Exposure to high stress in the intensive care unit may have negative effects on health-related quality-of-life outcomes after cardiac surgery. Crit Care Med 2003;31:1971–80.
268. Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41:263–306.
269. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016;17:131–57.
270. Zangrillo A, Bignami E, Biondi-Zoccai GG, Covello RD, Monti G, D’Arpa MC et al. Spinal analgesia in cardiac surgery: a meta-analysis of random- ized controlled trials. J Cardiothorac Vasc Anesth 2009;23:813–21.
271. Nader ND, Li CM, Dosluoglu HH, Ignatowski TA, Spengler RN. Adjuvant therapy with intrathecal clonidine improves postoperative pain in pa- tients undergoing coronary artery bypass graft. Clin J Pain 2009; 25:101–6.
272. Lena P, Balarac N, Arnulf JJ, Bigeon JY, Tapia M, Bonnet F. Fast-track cor- onary artery bypass grafting surgery under general anesthesia with remifentanil and spinal analgesia with morphine and clonidine. J Cardiothorac Vasc Anesth 2005;19:49–53.
273. White PF, Rawal S, Latham P, Markowitz S, Issioui T, Chi L et al. Use of a continuous local anesthetic infusion for pain management after median sternotomy. Anesthesiology 2003;99:918–23.
274. McDonald SB, Jacobsohn E, Kopacz DJ, Desphande S, Helman JD, Salinas F et al. Parasternal block and local anesthetic infiltration with levobupivacaine after cardiac surgery with desflurane: the effect on postoperative pain, pulmonary function, and tracheal extubation times. Anesth Analg 2005;100:25–32.
275. Cook TM, Counsell D, Wildsmith JA; Royal College of Anaesthetists Third National Audit Project. Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth 2009;102:179–90.
276. Richardson L, Dunning J, Hunter S. Is intrathecal morphine of benefit to patients undergoing cardiac surgery. Interact CardioVasc Thorac Surg 2009;8:117–22.
277. Engelman E, Marsala C. Efficacy of adding clonidine to intrathecal morphine in acute postoperative pain: meta-analysis. Br J Anaesth 2013; 110:21–7.
278. Yeung JH, Gates S, Naidu BV, Wilson MJ, Gao Smith F. Paravertebral block versus thoracic epidural for patients undergoing thoracotomy. Cochrane Database Syst Rev 2016;2:CD009121.
279. Canto M, Sanchez MJ, Casas MA, Bataller ML. Bilateral paravertebral blockade for conventional cardiac surgery. Anaesthesia 2003; 58:365–70.
280. Nasr DA, Abdelhamid HM, Mohsen M, Aly AH. The analgesic efficacy of continuous presternal bupivacaine infusion through a single catheter after cardiac surgery. Ann Card Anaesth 2015;18:15–20.
281. Agarwal S, Nuttall GA, Johnson ME, Hanson AC, Oliver WC Jr. A prospective, randomized, blinded study of continuous ropivacaine infusion in the median sternotomy incision following cardiac surgery. Reg Anesth Pain Med 2013;38:145–50.
282. Kocabas S, Yedicocuklu D, Yuksel E, Uysallar E, Askar F. Infiltration of the sternotomy wound and the mediastinal tube sites with 0.25% levobupi- vacaine as adjunctive treatment for postoperative pain after cardiac sur- gery. Eur J Anaesthesiol 2008;25:842–9.
283. Bainbridge D, Martin JE, Cheng DC. Patient-controlled versus nursecontrolled analgesia after cardiac surgery–a meta-analysis. Can J Anaesth 2006;53:492–9.
284. Greco M, Landoni G, Biondi-Zoccai G, Cabrini L, Ruggeri L, Pasculli N et al. Remifentanil in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2012;26:110–6.
285. Alavi SM, Ghoreishi SM, Chitsazan M, Ghandi I, Fard AJ, Hosseini SS et al. Patient-controlled analgesia after coronary bypass: remifentanil or sufentanil? Asian Cardiovasc Thorac Ann 2014;22:694–9.
286. Baltali S, Turkoz A, Bozdogan N, Demirturk OS, Baltali M, Turkoz R et al. The efficacy of intravenous patient-controlled remifentanil versus mor- phine anesthesia after coronary artery surgery. J Cardiothorac Vasc Anesth 2009;23:170–4.
287. Mamoun NF, Lin P, Zimmerman NM, Mascha EJ, Mick SL, Insler SR et al. Intravenous acetaminophen analgesia after cardiac surgery: a randomized, blinded, controlled superiority trial. J Thorac Cardiovasc Surg 2016;152:881–9.e1.
288. Jelacic S, Bollag L, Bowdle A, Rivat C, Cain KC, Richebe P. Intravenous acetaminophen as an adjunct analgesic in cardiac surgery reduces opi- oid consumption but not opioid-related adverse effects: a randomized controlled trial. J Cardiothorac Vasc Anesth 2016;30:997–1004.
289. Cattabriga I, Pacini D, Lamazza G, Talarico F, Di Bartolomeo R, Grillone G et al. Intravenous paracetamol as adjunctive treatment for postopera- tive pain after cardiac surgery: a double blind randomized controlled trial. Eur J Cardiothorac Surg 2007;32:527–31.
290. Ahlers SJ, Van Gulik L, Van Dongen EP, Bruins P, Tibboel D, Knibbe CA. Aminotransferase levels in relation to short-term use of acetaminophen four grams daily in postoperative cardiothoracic patients in the inten- sive care unit. Anaesth Intensive Care 2011;39:1056–63.
291. Kulik A, Bykov K, Choudhry NK, Bateman BT. Non-steroidal anti- inflammatory drug administration after coronary artery bypass surgery: utilization persists despite the boxed warning. Pharmacoepidemiol Drug Saf 2015;24:647–53.
292. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta- analyses of individual participant data from randomised trials. Lancet 2013;382:769–79.
293. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C et al. Duration of treatment with nonsteroidal anti- inflammatory drugs and impact on risk of death and recurrent myocar- dial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123:2226–35.
294. Qazi SM, Sindby EJ, Norgaard MA. Ibuprofen—a safe analgesic during cardiac surgery recovery? A randomized controlled trial. J Cardiovasc Thorac Res 2015;7:141–8.
295. Rafiq S, Steinbruchel DA, Wanscher MJ, Andersen LW, Navne A, Lilleoer NB et al. Multimodal analgesia versus traditional opiate based analgesia after cardiac surgery, a randomized controlled trial. J Cardiothorac Surg 2014;9:52.
296. Horbach SJ, Lopes RD, da C Guaragna JC, Martini F, Mehta RH, Petracco JB et al. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. Am J Med 2011;124:1036–42.
297. Stepensky D, Rimon G. Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs’ antiplatelet effects. Expert Opin Drug Metab Toxicol 2015; 11:41–52.
298. Acharya M, Dunning J. Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure? Interact CardioVasc Thorac Surg 2010;11:461–7.
299. Bainbridge D, Cheng DC, Martin JE, Novick R; Evidence-Based Perioperative Clinical Outcomes Research Group. NSAID-analgesia, pain control and morbidity in cardiothoracic surgery. Can J Anaesth 2006; 53:46–59.
300. Fayaz MK, Abel RJ, Pugh SC, Hall JE, Djaiani G, Mecklenburgh JS. Opioid-sparing effects of diclofenac and paracetamol lead to improved outcomes after cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18:742–7.
301. Kulik A, Ruel M, Bourke ME, Sawyer L, Penning J, Nathan HJ et al. Postoperative naproxen after coronary artery bypass surgery: a double- blind randomized controlled trial. Eur J Cardiothorac Surg 2004; 26:694–700.
302. Oliveri L, Jerzewski K, Kulik A. Black box warning: is ketorolac safe for use after cardiac surgery? J Cardiothorac Vasc Anesth 2014; 28:274–9.
303. Engoren MC, Habib RH, Zacharias A, Dooner J, Schwann TA, Riordan CJ et al. Postoperative analgesia with ketorolac is associated with decreased mortality after isolated coronary artery bypass graft surgery in patients already receiving aspirin: a propensity-matched study. J Cardiothorac Vasc Anesth 2007;21:820–6.
304. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and val- decoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481–92.
305. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081–91.
306. Grosen K, Drewes AM, Hojsgaard A, Pfeiffer-Jensen M, Hjortdal VE, Pilegaard HK. Perioperative gabapentin for the prevention of persistent pain after thoracotomy: a randomized controlled trial. Eur J Cardiothorac Surg 2014;46:76–85.
307. Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-ana- lysis. Br J Anaesth 2015;114:10–31.
308. Nesher N, Serovian I, Marouani N, Chazan S, Weinbroum AA. Ketamine spares morphine consumption after transthoracic lung and heart sur- gery without adverse hemodynamic effects. Pharmacol Res 2008; 58:38–44.
309. Tabatabaie O, Matin N, Heidari A, Tabatabaie A, Hadaegh A, Yazdanynejad S et al. Spinal anesthesia reduces postoperative delirium in opium dependent patients undergoing coronary artery bypass graft- ing. Acta Anaesthesiol Belg 2015;66:49–54.
310. Mehta Y, Kulkarni V, Juneja R, Sharma KK, Mishra Y, Raizada A et al. Spinal (subarachnoid) morphine for off-pump coronary artery bypass surgery. Heart Surg Forum 2004;7:E205–10.
311. Zakkar M, Frazer S, Hunt I. Is there a role for gabapentin in preventing or treating pain following thoracic surgery? Interact CardioVasc Thorac Surg 2013;17:716–9.
312. Lahtinen P, Kokki H, Hakala T, Hynynen M. S(+)-ketamine as an anal- gesic adjunct reduces opioid consumption after cardiac surgery. Anesth Analg 2004;99:1295–301.
313. Neuhauser C, Preiss V, Feurer MK, Muller M, Scholz S, Kwapisz M et al. Comparison of S-(+)-ketamine- with sufentanil-based anaesthesia for elective coronary artery bypass graft surgery: effect on troponin T levels. Br J Anaesth 2008;100:765–71.
314. Nesher N, Ekstein MP, Paz Y, Marouani N, Chazan S, Weinbroum AA. Morphine with adjuvant ketamine vs higher dose of morphine alone for immediate postthoracotomy analgesia. Chest 2009;136:245–52.
315. Kubal C, Srinivasan AK, Grayson AD, Fabri BM, Chalmers JA. Effect of risk-adjusted diabetes on mortality and morbidity after coronary artery bypass surgery. Ann Thorac Surg 2005;79:1570–6.
316. Ascione R, Rogers CA, Rajakaruna C, Angelini GD. Inadequate blood glu- cose control is associated with in-hospital mortality and morbidity in diabetic and nondiabetic patients undergoing cardiac surgery. Circulation 2008;118:113–23.
317. Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O’Brien PC et al. Intensive intraoperative insulin therapy versus conventional glu- cose management during cardiac surgery: a randomized trial. Ann Intern Med 2007;146:233–43.
318. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359–67.
319. Haga KK, McClymont KL, Clarke S, Grounds RS, Ng KY, Glyde DW et al. The effect of tight glycaemic control, during and after cardiac surgery, on patient mortality and morbidity: a systematic review and meta-ana- lysis. J Cardiothorac Surg 2011;6:3.
320. Giakoumidakis K, Eltheni R, Patelarou E, Theologou S, Patris V, Michopanou N et al. Effects of intensive glycemic control on outcomes of cardiac surgery. Heart Lung 2013;42:146–51.
321. Halkos ME, Puskas JD, Lattouf OM, Kilgo P, Kerendi F, Song HK et al. Elevated preoperative hemoglobin A1c level is predictive of adverse events after cor- onary artery bypass surgery. J Thorac Cardiovasc Surg 2008;136:631–40.
322. Marik PE. Tight glycemic control in acutely ill patients: low evidence of benefit, high evidence of harm! Intensive Care Med 2016;42:1475–7. 323. Preiser JC, Straaten HM. Glycemic control: please agree to disagree. Intensive Care Med 2016;42:1482–4.
324. Bhamidipati CM, LaPar DJ, Stukenborg GJ, Morrison CC, Kern JA, Kron IL et al. Superiority of moderate control of hyperglycemia to tight con- trol in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2011;141:543–51.
325. Lazar HL, McDonnell MM, Chipkin S, Fitzgerald C, Bliss C, Cabral H. Effects of aggressive versus moderate glycemic control on clinical out- comes in diabetic coronary artery bypass graft patients. Ann Surg 2011; 254:458–63; discussion 63–4.
326. Buchleitner AM, Martinez-Alonso M, Hernandez M, Sola I, Mauricio D. Perioperative glycaemic control for diabetic patients undergoing sur- gery. Cochrane Database Syst Rev 2012;9:CD007315.
327. Desai SP, Henry LL, Holmes SD, Hunt SL, Martin CT, Hebsur S et al. Strict versus liberal target range for perioperative glucose in patients undergoing coronary artery bypass grafting: a prospective randomized controlled trial. J Thorac Cardiovasc Surg 2012;143:318–25.
328. Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care 2015;38:1665–72.
329. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–97.
330. Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET et al. Perioperative hyperglycemia and risk of adverse events among pa- tients with and without diabetes. Ann Surg 2015;261:97–103.
331. Greco G, Ferket BS, D’Alessandro DA, Shi W, Horvath KA, Rosen A et al. Diabetes and the association of postoperative hyperglycemia with clin- ical and economic outcomes in cardiac surgery. Diabetes Care 2016; 39:408–17.
332. Mathioudakis N, Golden SH. A comparison of inpatient glucose man- agement guidelines: implications for patient safety and quality. Curr Diab Rep 2015;15:13.
333. Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V et al. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2005;130:1144.
334. Hua J, Chen G, Li H, Fu S, Zhang LM, Scott M et al. Intensive intraoperative insulin therapy versus conventional insulin therapy dur- ing cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2012; 26:829–34.
335. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125:1007–21.

Випадок успішної перикардіотомії з дренуванням перикардіальної порожнини в пацієнта з мультиморбідністю

Н.М. Середюк, А.В. Судус, І.М. Будзан, С.М. Гричинюк В.Б. Томин, Н.В. Рогів, М.В. Бєлінський, А.Я. Василишин

Література 

1. Humenyuk AF Aspects of rational treatment of cardiovascular patients with polymorphic lesions. Ukr Med Chasopys. 2009;5(73):25-32. (in Ukr.).
2. Kovalenko VМ. Еra of personalized medicine. Zdorovja Ukrainy. 2017;2(51):64.
3. Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine. Evid Based Med. 2010;15(6):165-166. (in Ukr.).
4. Caughey GE, Ramsay EN, Vitry AI. et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J Epidemiol Community Health. 2010;64(12):1036-1042.
5. Khan NK, Järvelä KM, Loisa EL. et al. Incidence, presentation and risk factors of late postoperative pericardial effusions requiring invasive treatment after cardiac surgery. Interact Cardiovasc Thorac Surg. 2017;24(6):835-840.
6. Mercer SW, Gunn J, Wyke S. Improving the health of people with multimorbidity: the need for prospective cohort studies. J Comorbidity. 2011;1:4-7.
7. Pepi M, Muratori B, Doria E. et al. Pericardial effusion after cardiac surgery: incidence, size, and haemodynamic. Consequence Brit Heard J. 1994;72(4):327-331.
8. Valderas JM, Starfield B, Sibbald B. et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357-363.
9. You SC, Shim CY, Hong GR. et al. Incidence, predictors and clinical outcomes of postoperative cardiac tamponade in patiens undergoing heart valve surgery. PL os One. 2016;11(11):165-754.